Artificial intelligence learns to make sense of childhood cancer survivors’ health care needs
Artificial intelligence (AI) could help physicians determine if survivors of childhood cancer need extra support…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
Simple tumour biomarker test predicts which stomach cancer patients will respond to immunotherapy
Researchers from Zhejiang Cancer Hospital and Peking University have discovered a new biomarker that can…
Copper overload kills cancer cells
Cuproptosis is fundamentally different from all previously known mechanisms of cell death: The deciding trigger…
Vaping likely to cause cancer: New findings
Nicotine-based vapes, or e-cigarettes, are likely to cause cancers of the lung and oral cavity,…
Shields and bodyguards: scientists uncover the hidden defences of a deadly childhood cancer
Researchers have created a detailed map of a deadly childhood cancer, showing it uses ‘shields’…
New genetic ‘roadmap’ advances precision therapy for intrahepatic cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of…
How often are appendiceal tumours missed in patients with acute appendicitis?
A retrospective cohort study published in JAMA Surgery has evaluated the prevalence and clinical significance…
AI triage shows no impact on lung cancer diagnostic timelines
Artificial intelligence (AI) is increasingly positioned as a potential solution to delays in lung cancer…
Culture, silence and safety: why oncology cannot afford to ignore its workforce
By Dr Dominique Lee Public trust in oncology relies on strong professional standards, transparent governance, and…
EBCC15: Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive
Results from the OASIS 4 clinical trial last year showed that a new drug, elinzanetant,…